StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Winrevair (sotatercept by Quarter

Winrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — International sales ($M) ($M)

Merck Winrevair (sotatercept: $66M in Q2 2026, up 450.0% from a year earlier. That is the highest of the 13 quarters on record here.

Latest, Q2 2026
66
Period ended Jun 30, 2026
Change on a year earlier
+450.0%
12 in Q2 2025
History
13 quarters
Since Q2 2023
Sources
9
Documents cited below

Where the Q2 2026 figure comes from

“|| Winrevair | 588 | 336 | 75 | 522 | 323 | 61 | 66 | 12 | *”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedWinrevair (sotatercept — PAH activin signaling inhibitor, launched Q2 2024) — International sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202666+450.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202648+300.0%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 202535+288.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202525+733.3%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202512–Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202512–Form 10-Q (filed 2026-05-04) ↗
Q4 2024Dec 31, 20249–Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 20243–Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 20240–Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 20240–Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 20230–Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2024-11-06) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-05) ↗

Cite this data

StockData. (2026). Merck Winrevair (sotatercept ($M), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-winrevair-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.